16th Jul 2024 15:30
GSK plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Emma Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 789 | ||||
£15.0500 | 1,311 | ||||
£15.0500 | 1,482
| ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
3,582 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Hal Barron | |||
b) | Position/status | Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W2044 | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 July 2024 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$38.9000 | 429 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Julie Brown | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 565 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Diana Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 123 | ||||
£15.0500 | 238 | ||||
£15.0500 | 373 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
734 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 152 | ||||
£15.0500 | 232 | ||||
£15.0500 | 378 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
762 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 71 | ||||
£15.0500 | 144 | ||||
£15.0500 | 234 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
449 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Luke Miels | |||
b) | Position/status | Chief Commercial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 259 | ||||
£15.0500 | 559 | ||||
£15.0500 | 704 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
1,522 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Shobie Ramakrishnan | |||
b) | Position/status | Chief Digital and Technology Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W2044 | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 July 2024 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$38.9000 | 26 | ||||
$38.9000 | 113 | ||||
$38.9000 | 175 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
314 $38.9000 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 172 | ||||
£15.0500 | 323 | ||||
£15.0500 | 448 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
943 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 156 | ||||
£15.0500 | 259 | ||||
£15.0500 | 539 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
954 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Philip Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 108 | ||||
£15.0500 | 169 | ||||
£15.0500 | 301 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 578 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0500 | 114 | ||||
£15.0500 | 413 | ||||
£15.0500 | 466 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
993 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Tony Wood | |||
b) | Position/status | Chief Scientific Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s)
| Price(s) | Volume(s) | ||
£15.0500 | 196 |
| |||
£15.0500 | 575 | ||||
| |||||
d) | Aggregated information
| ||||
Aggregated volume Price |
771 £15.0500 | ||||
e) | Date of the transaction | 2024-07-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Emma Walmsley | ||||
b) | Position/status | Chief Executive Officer | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GSK plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
e) | Date of the transaction | 2024-07-15 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024, on Ordinary Shares held within an ISA
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.2522 | 19 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-07-12 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Victoria Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024, on Ordinary Shares held within an ISA
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.2522 | 16 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-07-12 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
Related Shares:
Glaxosmithkline